- Home
- ORC vs MLYS Comparison
ORC vs MLYS Comparison
Compare ORC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORC
- MLYS
- Stock Information
- Founded
- ORC 2010
- MLYS 2019
- Country
- ORC United States
- MLYS United States
- Employees
- ORC N/A
- MLYS N/A
- Industry
- ORC Real Estate Investment Trusts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- ORC Real Estate
- MLYS Health Care
- Exchange
- ORC Nasdaq
- MLYS Nasdaq
- Market Cap
- ORC 623.6M
- MLYS 526.1M
- IPO Year
- ORC 2013
- MLYS 2023
- Fundamental
- Price
- ORC $8.28
- MLYS $10.21
- Analyst Decision
- ORC Buy
- MLYS Strong Buy
- Analyst Count
- ORC 3
- MLYS 2
- Target Price
- ORC $9.50
- MLYS $30.00
- AVG Volume (30 Days)
- ORC 3.0M
- MLYS 263.5K
- Earning Date
- ORC 01-30-2025
- MLYS 03-20-2025
- Dividend Yield
- ORC 17.43%
- MLYS N/A
- EPS Growth
- ORC N/A
- MLYS N/A
- EPS
- ORC 0.58
- MLYS N/A
- Revenue
- ORC $54,406,000.00
- MLYS N/A
- Revenue This Year
- ORC N/A
- MLYS N/A
- Revenue Next Year
- ORC N/A
- MLYS N/A
- P/E Ratio
- ORC $14.41
- MLYS N/A
- Revenue Growth
- ORC N/A
- MLYS N/A
- 52 Week Low
- ORC $7.41
- MLYS $8.58
- 52 Week High
- ORC $9.08
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- ORC 62.14
- MLYS 44.53
- Support Level
- ORC $7.88
- MLYS $9.57
- Resistance Level
- ORC $8.38
- MLYS $10.79
- Average True Range (ATR)
- ORC 0.18
- MLYS 0.64
- MACD
- ORC 0.04
- MLYS 0.11
- Stochastic Oscillator
- ORC 81.51
- MLYS 63.98
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc invests in residential mortgage-backed securities (RMBS) across the United States. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.